Clinical Trials Logo

Clinical Trial Summary

Aim of this study is to evaluate the effect of botulinum toxin type A (Xeomin®) on patients complaining from bruxism. The study will be a one arm clinical trial. Twelve subjects reporting bruxism irresponsive to conventional treatment modalities will be recruited and will be injected with botulinum toxin A (Xeomin®) in both masseter and temporalis muscles. Pain levels, Electromyographic activity and maximum occlusal force will be recorded in the subjects before injection and at 1 and 3 months after injection to determine the effect of treatment


Clinical Trial Description

Bruxism is a parafunctional activity of the masticatory muscles, characterized by jaw clenching and/or tooth grinding. It was suggested in international consensus conference that bruxism should have two distinct definitions. Sleep bruxism is a muscular action, either rhythmic or not, that takes place while sleeping, and an Awake bruxism which is a muscle disorder characterized by repeated or prolonged teeth contact with clenching of the jaw. Bruxism is a highly prevalent condition. More than 85% of the general population admit to bruxism at some time during their life. According to reports, the prevalence of awake bruxism is about 24% in the adult population, while the prevalence of bruxism when sleeping is estimated to be around 16% of the same population. The three muscles that responsible for the jaw closure and the majority of the biting force is the masseter, temporalis, and medial pterygoid muscles. About 43% of the intrinsic strength of jaw closure comes from the masseter, 36% from the temporalis, and 21% from the medial pterygoid. The diagnosis of bruxism is made on the basis of self-reporting of clenching or grinding the teeth, as well as evaluating tooth mobility, tooth wear, bruxism-related sounds, or jaw muscle pain and other clinical findings of the temporo-mandibular joint (TMJ). Bruxism has been noted in dentistry as a risk factor for tooth fracture and dental prosthesis damage, periodontal disease and possibly pain in the teeth, jaw, masticatory muscles, and temporo-mandibular joint. The etiology and pathophysiology of bruxism are still unknown, despite several potential causes have been suggested, including emotional stress, neurological diseases, specific medications, and occlusal interferences. Physical therapy, occlusal splints, and pharmacological management have all been investigated as potential treatment modalities for bruxism, but they have not been proven to be completely effective because they mostly treat patients' symptoms and signs rather than treating the underlying cause of the condition. These treatment modalities helped only in limiting the damaging effects of bruxism on the anatomical structures. Irreversible occlusal correction has been found ineffective and it is not supported by the available research. Occlusal splints have been applied to prevent overloading the temporomandibular joint elements and muscles of the jaw in addition to prevent tooth attrition. The efficacy of occlusal splints has given conflicting results. Botulinum toxin (Botox) is currently known to be a useful treatment for a wide range of neurological conditions, and it is used for its therapeutic and cosmetic effect. It is formed by the anaerobic bacterium Clostridium botulinum and has paralytic properties as it can inhibit acetylcholine release, which can ultimately inhibit muscle contraction. Botulinum toxin comes in seven forms : A, B, C, D, E, F, and G. Type A, which cleaves the plasma protein SNAP-25, is the most commonly used commercially and clinically. It is injected intramuscularly, and its effect lasts between three and six months and this transient denervation depends on the dose and volume of toxin. Since bruxism is caused by involuntary spasms of the jaw muscles, botulinum toxin has been experimented; initial results show that it is safe and effective. The injections generally take one week to start working and two weeks for a full effect, which lasts on average three to six months, and slowly wears off. The purpose of this study is to evaluate the efficacy of injecting botulinum toxin A into the masseter muscle in participants with bruxism, using a pain scale, Electromyography and occlusense device. The null hypothesis tested in this study is that there will be no significant difference in the pain level, muscles contractility and biting forces in patients injected with botulinum toxin ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05980559
Study type Interventional
Source Alexandria University
Contact Marwa M. Mohmed, Bachelors
Phone 00201224979900
Email Marwa.mohamed.dent@alexu.edu.eg
Status Not yet recruiting
Phase Phase 3
Start date January 15, 2024
Completion date April 15, 2024

See also
  Status Clinical Trial Phase
Completed NCT05760482 - Evaluation of the Relationship Between Bruxism and Tryptophan Metabolites N/A
Enrolling by invitation NCT02235220 - Reduction of Masticatory Muscle Activity by Restoring Canine Guidance N/A
Recruiting NCT05604729 - The Effect on Envelope of Motion in Asymptomatic Bruxers N/A
Recruiting NCT05995431 - Impact of Bruxism in the Outcome of Subgingival Instrumentation for the Management of Stage 2 and Stage 3 Periodontitis. N/A
Not yet recruiting NCT05764694 - Correlation Between the Occurrence of School Bullying, Victimization, and the Occurrence of Deleterious Oral Habits.
Completed NCT06258070 - Clinical Performance of Therapeutic Use of BTX for Bruxism N/A
Completed NCT04363931 - Investigation of the Effects of Kinesio Taping and Manual Therapy in Patients With Bruxism N/A
Terminated NCT01005511 - Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism N/A
Not yet recruiting NCT06052709 - Investigation of Occupational Balance in Individuals With and Without Bruxism N/A
Recruiting NCT06037798 - The Cranio-cervical Flexion Test Using the NOD Device
Recruiting NCT03006133 - Prevalence of Bruxism in a Group of Preschool Egyptian Children N/A
Completed NCT02257320 - TMJ NextGeneration(TM) Feasibility Study N/A
Completed NCT04884152 - Telerehabilitation in Individuals Temporomandibular Dysfunction With Bruxism N/A
Recruiting NCT04722809 - Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology Phase 3
Completed NCT01463826 - Respiratory Problems and Caries in Children With Bruxism N/A
Completed NCT05416788 - Effect of Cervical Manipulation on Mouth Opening N/A
Not yet recruiting NCT06386809 - Effectiveness of Transcutaneous Auricular Vagus Nerve Stimulation in Bruxism N/A
Recruiting NCT05562531 - Botulinum Toxin Administration on Masticatory Performance
Enrolling by invitation NCT06377475 - Fabrication and Insertion of Michigan Splints by Dental Students
Completed NCT04790110 - 7 Year Follow up Analysis on the Speed of Progression of Tooth Wear Using 3D Subtraction